Profile
Richard S.
Shames worked as a Senior Medical Director at Abbott Biotherapeutics Corp.
from 1999 to 2009, followed by a position as Scientist-Clinical Research at Merck & Co., Inc. from 2009 to 2013.
He then served as Chief Medical Officer at Aldea Pharmaceuticals, Inc. from 2013 to 2015 and later as Chief Medical Officer at Protagonist Therapeutics, Inc. from 2015 to 2019.
Prior to his industry positions, he was an Assistant Clinical Professor-Pediatrics at Stanford University and the University of California.
Shames received his undergraduate degree from Stanford University and his doctorate from the University of California.
Former positions of Richard S. Shames
| Companies | Position | End |
|---|---|---|
| PROTAGONIST THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 08/05/2019 |
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel enzyme activators to enhance the removal of toxic aldehydes | Chief Tech/Sci/R&D Officer | 31/12/2014 |
| MERCK & CO., INC. | Corporate Officer/Principal | 31/12/2012 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for the treatment of oncology and immunologic diseases | Corporate Officer/Principal | 31/12/2008 |
University of California
University of California Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Training of Richard S. Shames
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for the treatment of oncology and immunologic diseases | Health Technology |
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel enzyme activators to enhance the removal of toxic aldehydes | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures peptide based therapeutic products | Health Technology |
University of California
University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- Richard S. Shames
















